Skip to main content

ERRATUM article

Front. Immunol., 10 August 2021
Sec. Autoimmune and Autoinflammatory Disorders
Volume 12 - 2021 | https://doi.org/10.3389/fimmu.2021.748756

Erratum: Case Report: VEXAS Syndrome: From Mild Symptoms to Life-Threatening Macrophage Activation Syndrome

This article is an erratum on:

  1. Case Report: VEXAS Syndrome: From Mild Symptoms to Life-Threatening Macrophage Activation Syndrome

    1. Read original article
Frontiers Production Office* Frontiers Production Office*
  • Frontiers Media SA, Lausanne, Switzerland

An Erratum on:
Case Report: VEXAS Syndrome: From Mild Symptoms to Life-Threatening Macrophage Activation Syndrome

Staels F, Betrains A, Woei-A-Jin FJSH, Boeckx N, Beckers M, Bervoets A, Willemsen M, Neerinckx B, Humblet-Baron S, Blockmans DE, Vanderschueren S and Schrijvers R (2021). Front. Immunol. 12:678927. doi: 10.3389/fimmu.2021.678927

Due to a production error, an author name was incorrectly written as “Sherida Woei-A-Jin”, which did not match the citation. The correct name is “F J Sherida H Woei-A-Jin”. The publisher apologizes for this mistake.

The original version of this article has been updated.

Keywords: primary immunodeficiencies, autoinflammation, treatment reactions, myelodysplasia, ubiquitination

Citation: Frontiers Production Office (2021) Erratum: Case Report: VEXAS Syndrome: From Mild Symptoms to Life-Threatening Macrophage Activation Syndrome. Front. Immunol. 12:748756. doi: 10.3389/fimmu.2021.748756

Received: 28 July 2021; Accepted: 28 July 2021;
Published: 10 August 2021.

Copyright © 2021 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Production Office, cHJvZHVjdGlvbi5vZmZpY2VAZnJvbnRpZXJzaW4ub3Jn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.